throbber
Filed on behalf of: CSL Behring GmbH and CSL Behring LLC
`
`
`
`
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`__________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`__________________
`
`
`CSL BEHRING GMBH and CSL BEHRING LLC,
`Petitioners,
`
`
`v.
`
`
`SHIRE VIROPHARMA INC.,
`Patent Owner.
`
`_________________
`
`U.S. Patent No. 10,080,788
`Case No. IPR2019-00459
`_________________
`
`
`
`
`DECLARATION OF HANNO WALDHAUSER
`
`Page 1 of 9
`
`CSL EXHIBIT 1013
`
`

`

`DECLARATION
`
`I, Hanno Waldhauser, declare:
`
`I am a permanent and full—time employee of CSL Behring. I am a
`
`trained commercial clerk and marketing / communication specialist and currently
`
`hold the position of Therapy Area Director EU.
`
`I was acting as Senior Global
`
`Product Manager in March 2012.
`
`Each year, academic and clinical leaders, as well as marketing directors
`
`and product managers attend the American Academy of Allergy, Asthma &
`
`Immunology (“AAAAI”) Annual Meeting, which showcases new research and
`
`developments in the areas of allergy, asthma, and immunology. See Ex. 1084 [2012
`
`Exhibitor Prospectus], p. 2.
`
`In 2012 the AAAAI annual meeting was held from
`
`March 2 to March 6 in Orlando, Florida. Ex. 1084 [2012 Exhibitor Prospectus, p. l],
`
`I attended that meeting, and a photograph of my access badge is provided as
`
`Exhibit 1085. The meeting was attended by nearly 5,000 delegates from over 60
`
`countries and featured 960 abstracts, 370 educational sessions, and 144 exhibitors.
`
`See Ex. 1086 [eNews Meeting Summary, p. 1],
`
`l. Attendees included an
`
`international audience of primarily physicians and specialists in the area of allergy
`
`and immunology, as well as academics and industry representatives of companies
`
`who operate in the same field, most of them having exhibitor booths during the
`
`conference. See Ex. 1087 [2012 AAAAI Meeting Program].
`
`Page 2 of 9
`
`

`

`3.
`
`Exhibit 1004 is a true and accurate reproduction (scanned copy) of a
`
`hardcopy handout of a poster
`
`titled “Safety, Pharmacokinetics
`
`(PK), and
`
`Phannacodynamics (PD) of Subcutaneous (SC) CINRYZE® (Cl Esterase Inhibitor
`
`[Human]) with Recombinant Human Hyaluronidase (rHuPH20) in Subjects with
`
`Hereditary Angioedema (HAE)” by J. Schranz et al. that was displayed during the
`
`2012 AAAAI annual meeting (“Schranz poster”). The METHODS section of the
`
`poster (enlarged as Ex. 1088 [Enlarged Schranz Figure 1]) includes “Figure 1. Study
`
`Design,” which provides a simple graphical representation of a “Prior 200 Study”
`
`and a “Current 204 Study.”
`
`The Figure discloses that CINRYZE® was
`
`subcutaneously administered to participants in the “Prior 200 Study” at a
`
`concentration of 333.3U/mL (1,000U in 2 separate injections of 1.5mL or 2,000U in
`
`4 separate injections of 1.5mL).
`
`The Schranz poster was displayed during the poster session held on
`
`Tuesday, March 6th, at 9:45 AM ET in the poster viewing area / hall close to the
`
`industry exhibition area of the conference and was accessible to all registered
`
`delegates and exhibitors of the conference. See Ex. 1087 [2012 AAAAI Meeting
`
`Program, p. 123—29], 125—31. Exhibit 1089 is a photograph of the poster in the
`
`poster viewing hall taken by me during the AAAAI annual meeting poster session.
`
`Id. As discussed in paragraph 2,
`
`there were approximately 5,000 people in
`
`attendance at the conference, all of whom were permitted to View the poster, take
`
`copies of the poster that were made available to the attendees, and also photograph
`
`Page 3 of 9
`
`

`

`the poster, as I did.1 In my recollection, the poster was presented by one of the
`
`authors on-site, as requested by the conference.
`
`See Exhibit 1090 [Poster
`
`Presentation Instructions, p. 1], 1. In my recollection, the poster was discussed with
`
`physicians who were actively treating patients
`
`suffering from Hereditary
`
`Angioedema (“HAE”), and with industry representatives of manufacturers of HAE
`
`therapies (including CSL Behring) while it was on display.
`
`Presenting authors, as well as representatives of ViroPharma (at that
`
`time ViroPharma was sponsoring the research of the study which results were
`
`presented in the Schranz poster) were present on-site (i.e., near the poster) and
`
`provided answers to viewers. Handouts of the poster were freely available to those
`
`attending the annual meeting.2 A copy of the handout was brought back to CSL
`
`Behring, and copies were then distributed within the company.
`
`I personally
`
`distributed copies of the handout to my medical and marketing colleagues within
`
`CSL Behring a few days after the 2012 AAAAI annual meeting.
`
`1 My colleague, Dr. Thomas Machnig, who is a trained physician and medical
`
`doctor (MD) for internal medicine and holds the position of Director Medical
`
`Affairs at CSL Behring, was also in attendance and viewed the Schranz poster.
`
`2 While I do not know how many copies of the Schranz poster were taken by viewers
`
`during the meeting, I note that my colleagues at CSL Behring typically distribute
`
`between 50—100 copies of the posters we have presented at similar conferences.
`
`Page 4 of 9
`
`

`

`6.
`
`On February 9, 2012, the Journal of Allergy and Clinical Immunology
`
`published the abstract of the Schranz poster online. See Ex. 1091 [Schranz Poster
`
`Abstract, p. AB3 69 (L21)], 3. The same day that the Schranz poster was presented,
`
`ViroPharma and Halozyme issued a press release through the PR Newswire service
`
`titled “ViroPharma and Halozyme Announce Positive Data of Subcutaneous
`
`Cinryze® (C1 esterase inhibitor [human]) with Recombinant Human Hyaluronidase
`
`(rHuPHZO)” (confirming the presentation of a poster by Jennifer Schranz entitled
`
`“Safety, Phrmacokinetics (PK), and Pharmacodynamics (PD) of Subctuaneous (SC)
`
`Cinryze® (C1 inhibitor
`
`(C1 INH) with Recombinant Human Hyaluronidase
`
`(rHuPH20) in Subjects with Hereditary Angioedema (HAE) at the 2012 annual
`
`AAAAI meeting held March 2—6 in Orlando, Florida. See Exhibit 1092 [Halozyme
`
`Press Release, p. 1—3], 1—3. In addition, IMP Securities published a “Biotechnology
`
`— Company Report” of ViroPharma Inc. the day after the poster was presented
`
`(March 7, 2012). See Ex. 1093 [IMP Company Report, p. 1—2],
`
`l—2. The report
`
`mentions that the presentation of the Schranz poster took place at the 2012 AAAAI
`
`Annual Meeting and includes a summary of the poster together with Figure 2 of the
`
`Schranz poster (presented as Figure l in the report), which presented data regarding
`
`the mean plasma Cl-INH Functional Concentration. Id. This further confirms the
`
`public availability of the Schranz poster.
`
`I declare that all statements made herein of my own knowledge are true
`
`and the statements made herein on information and belief are believed to be true.
`
`I
`
`Page 5 of 9
`
`

`

`further declare that all statements made herein were made with the knowledge that
`
`willful false statements and the like are punishable by fine or imprisonment or both
`
`pursuant to 18 U.S.C. § 1001.
`
`In signing this declaration, I understand that the declaration will be filed
`
`as evidence in a contested case before the Patent Trial and Appeal Board of the
`
`United States Patent and Trademark Office. I acknowledge that I may be subject to
`
`cross examination in the case and that cross examination will take place within the
`
`United States.
`
`If cross examination is required of me, I Will appear for cross
`
`examination within the United States during the time allotted for cross examination.
`
`I [Illi/ZZ/g
`
`Page 6 of 9
`
`

`

`
`
`Appendix A
`Appendix A
`
`
`
`
`
`
`
`
`
`Page 7 of 9
`
`Page 7 of 9
`
`

`

`APPENDIX A
`
`List of Materials Cited
`
`DESCRIPTION
`
`Jennifer Schranz et al., Safety, Pharmacokinetics (PK), and
`Pharmacodynamics (PD) ofSubcutaneous (SC) CINR YZE® (CI
`Esterase Inhibitor [Human]) with Recombinant Human
`Hyaluronia'ase (rHuPH20) in Subjects with Hereditary
`Angioedema (HAE), VIROPHARMA INC., Mar. 2—5, 2012
`American Academy of Allergy, Asthma, & Immunology Annual
`Meetin Poster L21 “Schranz” .
`
`
`
`
`
`
`
`
`
`
`
`Exhibitor Prospectus from 2012 American Academy of Allergy,
`
`Asthma & Immunology (AAAAI) Annual Meeting in Orlando,
`Florida (March 2—6, 2012),
`
`h - ://annua1meetin.aaaai.or- de/2012-exhibitora . df.
`
`Delegate badge of Hanno Waldhauser from AAAAI 2012 Annual
`Meetin .
`
`
`Thousands Assemble in Orlandofor the 2012 Annual Meeting,
`ENEWS NOW (June 2018), http://enews.aaaai.org/april-
`
`
`20 12/news=briefs/thousands-assemble-in-orlando-for-the—2012-
`
`
`
`annual-meetin ; downloaded on Nov. 9, 2018 .
`
`Final Program from AAAAI 2012 Annual Meeting,
`
`
`http://www.aaaai.org/Aaaai/media/MediaLibrary/PDF%20Docu
`
`ments/VAM/AAAAI AM-12-Final-Pro- am EDU-Content. df.
`
`
`
`
`
`
`Enlared exce ts from Ex.1004.
`Photograph of Ex. 1004 taken at the 2012 AAAAI Annual
`Meetin; on Mar. 6,2012.
`Poster Presentation Information & Set-up Instructions,
`2018 AAAAI/WAO JOINT CONGRESS,
`http://annualmeeting.aaaai.org/UserFiles/AbstractPresenterInstru
`
`ctions. .df.
`
`XHEIBIT
`
`Ex. 1004
`
`Ex. 1084
`
`Ex. 1085
`
`Ex. 1086
`
`Ex. 1087
`
`Ex. 1088
`Ex. 1089
`
`EX. 1090
`
`Ex. 1091
`
`
`
`
`
`
`
`J. Schranz et al., Safety, Pharmacokinetics (PK), and
`
`Pharmacodynamics (PD) ofSubcutaneous (SC) CINRYZE® (CI
`
`
`Esterase Inhibitor [Human])with Recombinant Human
`
` Hyaluronidase (rHuPH20) in Subjects with Hereditary
`
`Angioedema (HAE), ViroPharma Incorporated, 129(2)
`
`
`J. ALLERGY & CLIN. IMMUNOL. AB369 (Abstract L21) (2012),
`WWW.sciencedirect.com/science/article/pii/SOO91674912000280
`
`
`(downloaded Sept. 25 2018 .
`
`Press Release from Halozyme Therapeutics, ViroPharma and
`
`Halo me Announce Positive Data 0 Subcutaneous Cin ze®
`
`
`
`
`
`Ex. 1092
`
`
`
`

`

`EXHIBIT
`
`
`
`
`
`
`
`
`
`Ex. 1093
`
`(CI esterase inhibitor [human]) with Recombinant Human
`Hyaluronidase (rHuPHZO) (Mar. 6, 2012),
`http://Www.halozyme.com/investors/news-re1eases/news—release-
`details/2012/ downloaded on Ar. 13, 2016 .
`Liisa A. Bayko et al., ViroPharma Incorporated Company
`Reort IMP SECURITIES Mar. 7 2012 .
`
`DESCRIPTION
`
`
`
`
`
`
`
`
`

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket